IRA negotiation cut Stelara's Medicare price 66% while biosimilars erode adalimumab and ustekinumab — squeezing net price from two directions at once.
Commercial and Medicare access to psoriasis biologics runs through utilization management: most plans require patients to try and fail conventional systemics and often one preferred biologic (a 'try-two-fail' step edit) before covering a branded IL-17 or IL-23 agent. ICER's 2018 targeted-immunomodulator assessment found IL-17 agents produced better outcomes than older TNF inhibitors, put cost-per-QALY across the class between roughly $131,000 (brodalumab) and $188,000 (certolizumab pegol), and explicitly urged payers to limit or abolish step therapy given the class's value relative to non-targeted care.
Two pricing shocks now overlay that access architecture. Under the Inflation Reduction Act, Medicare selected Stelara (ustekinumab) and Enbrel (etanercept), both psoriasis agents, in the first negotiation cycle; effective January 1, 2026, Stelara's negotiated 30-day-equivalent price is $4,695 versus a $13,836 list (a 66% reduction) and Enbrel's is $2,355 versus $7,106 (67%). Simultaneously, biosimilars are eroding the legacy anchors: 9–10 adalimumab (Humira) biosimilars launched across 2023 (Amjevita first in January, a wave of eight in July), and ustekinumab (Stelara) biosimilars began US launches in January 2025, led by Wezlana as the first interchangeable. Branded strategy is retreating to the IL-23 and dual-IL-17 mechanisms that biosimilars and negotiation have not yet reached.
US access and pricing levers for plaque psoriasis biologics: step therapy, IRA negotiation, biosimilars and HTA value.
| Lever | Detail | Source |
|---|---|---|
| Medicare IRA negotiation — Stelara | Negotiated $4,695 vs $13,836 list (66% cut), 30-day equivalent, effective Jan 1, 2026 | CMS / HHS ASPE |
| Medicare IRA negotiation — Enbrel | Negotiated $2,355 vs $7,106 list (67% cut), effective Jan 1, 2026 | CMS / HHS ASPE |
| Adalimumab (Humira) biosimilars | 9–10 launched in 2023; Amjevita first (Jan), eight more in July; Cyltezo first interchangeable | Amgen; AJMC; Center for Biosimilars |
| Ustekinumab (Stelara) biosimilars | US launches began Jan 2025; Wezlana first interchangeable; ≥4 on market | FDA; Center for Biosimilars |
| Payer step therapy | 'Try-two-fail' edits (conventional systemic + preferred biologic) common before branded IL-17/IL-23 | ICER 2018 assessment (recommended limiting) |
| HTA value benchmark (ICER 2018) | IL-17 > TNF on outcomes; cost/QALY ~$131k (brodalumab) to ~$188k (certolizumab pegol) | ICER targeted immunomodulators report |
Sources: IRA negotiated prices and selection from CMS Medicare Drug Price Negotiation fact sheets and HHS ASPE (Stelara $4,695 vs $13,836; Enbrel $2,355 vs $7,106; effective Jan 1, 2026). Adalimumab biosimilar launch counts from Amgen and AJMC; ustekinumab biosimilar launches and Wezlana interchangeability from FDA and Center for Biosimilars. Cost-effectiveness and step-therapy guidance from ICER's 2018 targeted-immunomodulators for plaque psoriasis assessment.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- A net-price and rebate-erosion map by mechanism, separating negotiation-exposed from biosimilar-exposed assets
Delivers
- A step-therapy prevalence and exception-pathway read against ICER's value verdicts
Delivers
- A biosimilar-uptake trajectory from the 2023 adalimumab precedent applied to the 2025 ustekinumab launches
Custom assessment delivered in 72 hours.
Commission This AssessmentWhat's inside
- The 'try-two-fail' step edit requiring conventional systemic plus a preferred biologic before branded IL-17/IL-23 coverage
- ICER's 2018 finding that IL-17 agents outperform older TNF inhibitors, and its call to limit or abolish step therapy
- ICER's 2018 cost-per-QALY range spanning roughly $131,000 for brodalumab to $188,000 for certolizumab pegol
- How this value range factored into ICER's step-therapy-limitation recommendation for payers
- Stelara's negotiated 30-day-equivalent price of $4,695 versus a $13,836 list, a 66% reduction effective January 1, 2026
- Enbrel's negotiated price of $2,355 versus $7,106 list, a 67% reduction on the same effective date
- The 9-10 adalimumab biosimilars launched across 2023, led by Amjevita in January and an eight-product wave in July
- Ustekinumab biosimilars beginning US launches in January 2025, led by Wezlana as the first interchangeable
- How Skyrizi, Tremfya, Cosentyx, Taltz, Bimzelx, and Sotyktu were excluded from the first IRA negotiation cycle unlike Stelara and Enbrel
- The net-price and rebate-erosion map separating negotiation-exposed from biosimilar-exposed assets
- Why branded strategy is retreating toward IL-23 and dual-IL-17 mechanisms that biosimilars and negotiation have not yet reached
- The projected trajectory of ustekinumab biosimilar uptake following the 2023 adalimumab erosion precedent
Included with every brief
How AXLRx builds this assessment
Prepared by MoatRx analysts.
Every AXLRx assessment is built from primary regulatory sources (FDA, ClinicalTrials.gov), peer-reviewed literature, and live payer policy documentation — not secondary summaries. No secondary summaries, market research reports, or unverified estimates are used. Findings are independently verified before inclusion.
US Plaque Psoriasis Payer & HTA sources: CMS/HHS ASPE (IRA negotiated prices), FDA (biosimilar approvals), ICER assessment, and live payer coverage documentation.
- IRA scope confirmed against CMS/ASPE: Stelara and Enbrel are first-cycle selected drugs with negotiated prices effective Jan 1, 2026. The psoriasis market's leading IL-23 and IL-17 brands (Skyrizi, Tremfya, Cosentyx, Taltz, Bimzelx, Sotyktu) were not in the first cycle.
- Biosimilar facts corroborated across FDA and trade press: adalimumab first biosimilar Amjevita (Jan 2023), eight-product July 2023 wave; ustekinumab Wezlana first interchangeable, US launch Jan 2025.
- ICER cost/QALY range ($131k brodalumab – $188k certolizumab) and step-therapy recommendation attributed to the ICER 2018 report, treated as HTA opinion rather than primary trial data.
Frequently asked questions
Commission this assessment
AXLRx delivers US Plaque Psoriasis payer & hta built for pharma and biotech commercial, access, and medical affairs teams. Custom assessment in 72 hours.
Use the intake form to specify your indication, geography, and commercial question.
AXLRx analyst confirms scope, comparators, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.